SOMERSET, N.J.--(BUSINESS WIRE)--Jan 3, 2023--

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases today announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA.

CEO Ying Huang, PhD will deliver the company presentation on Tuesday, January 10, 2023 at 2:15 pm (Pacific Time).

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005568/en/

CONTACT: Investor Contacts:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

joanne.choi@legendbiotech.comCrystal Chen, Manager, Investor Relations, Legend Biotech

crystal.chen@legendbiotech.comPress Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech

tina.carter@legendbiotech.com

(908) 331-5025

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW JERSEY

INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH

SOURCE: Legend Biotech

Copyright Business Wire 2023.

PUB: 01/03/2023 04:01 PM/DISC: 01/03/2023 04:01 PM

http://www.businesswire.com/news/home/20230103005568/en